FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OIVIB APPROV	AL
OMB Number:	3235-028
Estimated average burd	den
hours per response	0.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1 Name an																
1. Name and Address of Reporting Person Furey John (Last) (First) (Middle) C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK (Street)				2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]					x_	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner Officer (give title below) Other (specify below)						
				Date of Earliest Transaction (Month/Day/Year) 07/01/2021 4. If Amendment, Date Original Filed(Month/Day/Year)												
										X Fo	6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
ABINGDON, X0 OX144RX (City) (State) (Zip)					Table I - Non-Derivative Securities Acqu						quired, 1	ured, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year		Execution Date, if any (Month/Day/Year)			(A	. Securities Acquired A) or Disposed of (D) Instr. 3, 4 and 5)		Owned Following Reported Transaction(s)		O Fo	wnership or orm: B	eneficial				
				Pay/Year)		de V Ar	(A) or Amount (D)		(Instr.	Instr. 3 and 4)		or (I)	Indirect (I	wnership nstr. 4)		
Reminder: I												ection of i espond un		orm displays		74 (9-02)
								in this fo		requir	ed to re	espond un				74 (9-02)
1. Title of	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	4. Transact Code	tion Do Se or (E	Alls, warranteed. Number Derivative ecurities acquired (propose D)	of (A) ed of	in this fo	orm are not tly valid Of ed of, or Beservertible secu isable and tte	require IB con reficiall rities) 7. T of U Sec	ed to rentrol number	Amount	less the f	9. Number of Derivative Securities Beneficially Owned Following	10. Ownership Form of Derivative Security: Direct (D)	11. Natu of Indire Benefici Ownersh (Instr. 4)
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transact Code	tion Second (I	Alls, warr Number Derivative ecurities Acquired (or Dispose	of (A) ed of	in this for a current uired, Dispos, options, con 6. Date Exerc Expiration Date	orm are not tly valid Of ed of, or Beservertible secu isable and tte	require IB con reficiall rities) 7. T of U Sec	red to rentrol number of the state of the st	Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natu of Indire Benefici Ownersl (Instr. 4

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Furey John C/O ADAPTIMMUNE THERAPEUTICS PLC 60 JUBILEE AVE, MILTON PARK ABINGDON, X0 OX144RX	X					

Signatures

/s/ John Furey	07/02/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise price was converted from GBP0.51 based on an exchange rate of \$U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.